Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.

Authors :: Matsuda K
Nakazawa Y
Iwashita C
Kurata T
Hirabayashi K
Saito S
Tanaka M
Yoshikawa K
Yanagisawa R
Sakashita K
Sasaki S
Honda T
Koike K
Source :: Leukemia [Leukemia] 2014 Jul; Vol. 28 (7), pp. 1545-8. Date of Electronic Publication: 2014 Feb 05.
Publication Year :: 2014

Subjects :: Child, Preschool
Drug Resistance, Neoplasm genetics
Female
Humans
Infant
Leukemia, Myelomonocytic, Juvenile metabolism
Male
Signal Transduction
Treatment Outcome
Leukemia, Myelomonocytic, Juvenile drug therapy
Leukemia, Myelomonocytic, Juvenile genetics
Mercaptopurine pharmacology
Mercaptopurine therapeutic use
Mutation
Neoplastic Stem Cells drug effects
Neoplastic Stem Cells metabolism
Protein Tyrosine Phosphatase, Non-Receptor Type 11 genetics

Full Text Access

Tools